Satsuma Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
August 12, 2020 01:55 ET
|
Satsuma Pharmaceuticals
Completed treatment phase of pivotal EMERGE™ Phase 3 efficacy trial of STS101 as planned and remain on track to report top-line results in late September or early October 2020Initiated patient...
Satsuma Pharmaceuticals Announces Enrollment of First Patient in the ASCEND™ Phase 3 open-label, safety trial of STS101
August 06, 2020 16:01 ET
|
Satsuma Pharmaceuticals
ASCEND results expected to support STS101 NDA filing in Q4 2021 SOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage...
Satsuma Pharmaceuticals Announces the Appointment of Thomas M. Soloway to its Board of Directors
July 07, 2020 16:01 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that it has appointed...
Satsuma Pharmaceuticals to Present Two Posters at the American Headache Society’s Annual Scientific Meeting Hosted via a Virtual Meeting Platform
June 11, 2020 16:05 ET
|
Satsuma Pharmaceuticals
Meeting Launch date is Saturday, June 13th 2020 at 9:00am (PT) Safety of Dihydroergotamine for the Acute Treatment of Migraine: Reality vs Perception The Efficacy of Dihydroergotamine versus...
Satsuma Completes Enrollment in Pivotal Phase 3 EMERGE trial of STS101 for Acute Treatment of Migraine
June 01, 2020 16:05 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today reported completion of enrollment and...
Satsuma Pharmaceuticals to To Present at the Jefferies Virtual Healthcare Conference
May 27, 2020 08:30 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, President...
Satsuma Pharmaceuticals Announces Poster Presentations on the American Academy of Neurology 2020 Science Highlights Virtual Platform
May 18, 2020 16:05 ET
|
Satsuma Pharmaceuticals
Pharmacokinetic comparison of STS101, an intranasal dry powder formulation of dihydroergotamine, with other intranasal, injectable and oral inhaled DHE formulations Water-insoluble...
Satsuma Pharmaceuticals Reports First Quarter 2020 Financial and Business Results
May 12, 2020 16:01 ET
|
Satsuma Pharmaceuticals
STS101 EMERGE™ Phase 3 efficacy trial remains on track with announcement of topline data expected in second half of 2020 Company well-capitalized with cash, cash equivalents, and marketable...
Satsuma Pharmaceuticals to Host Key Opinion Leader Event: STS101 and the Acute Treatment of Migraine
April 28, 2020 16:05 ET
|
Satsuma Pharmaceuticals
SOUTH SAN FRANCISCO, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, announced today that it will host a Key...
Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Results
March 10, 2020 16:01 ET
|
Satsuma Pharmaceuticals
On track to announce topline data in second half of 2020 from Phase 3 EMERGE™ efficacy trial evaluating STS101 for the acute treatment of migraine Company well-capitalized with cash, cash...